Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Bristol-Myers Squibb Maxipime

Executive Summary

Bristol-Myers Squibb Maxipime: Cefepime approved for supplemental indication of monotherapy for empiric treatment of febrile neutropenic patients. Maxipime is the first antibiotic approved for the indication. Recommended dosing is two grams I.V. every eight hours for seven days or until resolution of neutropenia. NDA 50-679/SE1-002 was submitted May 17, 1996 and approved May 16...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel